LYTIX BIOPHARMA ASA: årsregnskap 2019 vs 2018
Shrank 43% on revenue, stronger earnings, cash halved-plus
approved 2020-05-28; registry 2020-07-25; journal 2020 603521
Summary
What changed
Comparing Årsregnskap 2019 with 2018 for LYTIX BIOPHARMA ASA. Revenue 11.84m NOK → 6.70m NOK (-43.4%). Net result -61.52m NOK → -33.23m NOK. Equity 41.05m NOK → 14.39m NOK.
On the constructive side: net result improved. Pressures included: revenue fell; equity eroded; cash fell.
Also worth watching: sharp cash drawdown; paid-in equity reduced. All figures are taken from the published annual accounts for LYTIX BIOPHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Net result improved
Net result -61.52m NOK → -33.23m NOK (net margin -519.6% → -496.1%). Calculated
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 11.84m NOK to 6.70m NOK (-43.4% YoY). Calculated
-
↓
Equity eroded
Book equity 41.05m NOK → 14.39m NOK (equity ratio 69.7% → 82.6%). Calculated
-
↓
Cash fell
Bank deposits 49.62m NOK → 12.80m NOK (-74.2% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (49.62m NOK → 12.80m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 37.05m NOK → 14.39m NOK — check capital reduction, conversion, or reclassification. Interpretation